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It's time to treat systemic sclerosis
S
ystemic sclerosis (SSc) is still one of the most diffi-
cult therapeutic challenges in the field of rheumatic 
autoimmune diseases. However, many developments 
took place in the last decade, linked to an earlier diag-
nosis and treatment and better characterization of the clinical 
and epidemiological profile of the disease. If an early diagnosis 
of the cutaneous and visceral involvement is established, more 
efficient organ-specific strategies can be proposed. Within this 
philosophy, 2009 began with the first publication of recommen-
dations for the SSc treatment by expert members of the EULAR 
Scleroderma Trials and Research Group (EUSTAR).1 Another 
sign of this growing interest is that the current edition of the 
Brazilian Journal of Rheumatology (BJR) has two national 
studies about therapeutics on SSc.2,3
 Two situations exert striking influence in the treatment 
of systemic sclerosis: fibrosis and an altered vascular endo-
thelium. Several drugs have been used for its anti-fibrotic 
activity, especially in diffuse thickening of the skin and 
interstitial lung disease. The use of cyclophosphamide4 and 
immunosuppressants5 in SSc has been recently described 
and analyzed. However, the only randomized, double-blind, 
placebo-controlled studies with cyclophosphamide were 
only published in 2006,6,7 with favorable results but without 
significant statistic expression. The Scleroderma Lung Study 
(SLS), a multicenter study conducted in the United States un-
der the sponsorship of the National Institute of Health (NIH), 
has evaluated 158 patients using oral cyclophosphamide (or 
placebo) for a period of one year, and the patients have been 
followed for a total of two years; there was statistically sig-
nificant improvement in primary and secondary endpoints.6 
In subsequent years, the SLS Research Group has published 
several other articles, deeply analyzing different aspects of the 
study, such as lung function and skin score,8 the SSc clinical 
forms,9 the quality of life,10 the bronchoalveolar lavage,11 and 
assessment parameters of thorax high-resolution computed 
tomography (HRCT).12 The other study was the FAST, which 
evaluated 45 patients with SSc and active alveolitis in England 
and treated with intravenous cyclophosphamide (or placebo) 
for 12 months, then using azathioprine for other 12 months. 
The primary and secondary endpoints were not statistically 
significant and the statistical trend in forced vital capacity 
(FVC) improvement was only observed in patients who used 
cylophosphamide.7 The results of these two controlled studies 
have enabled that the cyclophosphamide could be considered 
and indicated as treatment of SSc interstitial lung disease 
according to EUSTAR1 recommendations, which still require 
further work to consider cyclophosphamide as treatment for 
aggressive cutaneous features, which are predominant in early 
diffuse SSc.
  In the current edition of BJR, Macedo et al.2 have exami-
ned the clinical course of nine patients with diffuse SSc and 
total skin score (TSS) > 30 without severe visceral involvement 
who made use of intravenous cyclophosphamide for 18 months 
and were followed at the Universidade de São Paulo (USP). 
Significant TSS reduction in the 12 months was observed 
(Mean TSS ± standard deviation (SD): 37.77 ± 4.08 vs. 29.22 ± 
8.13, P = 0009), held after 18 months of treatment (Mean TSS 
± SD: 26.42 ± 10.08, P = 0.01), without serious side effects. 
Ten years ago, we also published on BJR the experience at 
the Universidade Estadual de Campinas (UNICAMP) with 
intravenous cyclophosphamide in the treatment of 45 patients 
with SSc. Thirteen of them had rapidly progressive diffuse SSc 
and also presented statistical improvement at the TSS.13 Further 
studies with more patients and a longer follow-up are needed 
to confirm the capacity of improvement of skin thickening with 
the use of cyclophosphamide in SSc.
 Among the vasoactive drugs, there are some with excellent 
safety profile and efficacy in the treatment of scleroderma renal 
crisis14 and pulmonary hypertension.15 As the patients with 
SSc present an improvement in their mean survival, events 
such as the occurrence of digital ischemic ulcers become more 
frequent.16,17 The traditional calcium-channel blockers (such as 
nifedipine and diltiazen) are more effective in preventing new 
attacks in patients with primary Raynaud’s phenomenon.18 The 
most complicated ischemic ulcers can be treated with the use 
of iloprost19,20, treprostinil21, bosentan22,23, and sildenafil.24,25 
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However, beyond the treatment of crisis, these extremely 
painful and disabling ulcers should also have a prevention 
treatment. The EUSTAR group’s recommendations for the SSc 
treatment consider that nifedipine, the prostanoids (especially 
the intravenous iloprost) and bosentan may be used to prevent 
the recurrence of ischemic ulcers in SSc.1
 Two prospective multicenter, randomized, double-blind, 
placebo-controlled studies (Rapids-1 and Rapids-2), examining 
patients in 17 centers in Europe and North America, showed 
that bosentan can prevent the occurrence of new digital ulcers, 
but not accelerate the healing of ulcers present at the time of 
randomization, in SSc patients with recurrent ulcers.26, 27 Based 
on the results of these studies, Mariz et al.3 (at this issue BJR), 
used the oral bosentan in the treatment of active refractory 
ischemic ulcers in three patients at the Universidade Federal 
de São Paulo (UNIFESP), contributing to the healing and pre-
vention of the occurrence of new ulcers in a short follow-up of 
12 weeks. The different healing responses seem to reside in the 
heterogeneity of the definition of active ischemic ulcers.28
Concluding, for rheumatologists interested in early diag-
nosis and treatment of SSc, the detailed analysis of different 
epidemiological and clinical parameters, that govern the 
different therapeutic responses in the disease, is essential in 
choosing the best medication for each phase of the development 
of SSc, thus optimizing patients’ expectations, treatment costs 
and side effects.
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